Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide
- PMID: 3380783
- PMCID: PMC280377
- DOI: 10.1073/pnas.85.12.4118
Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide
Abstract
Didemnin B, a highly active depsipeptide isolated from a Caribbean tunicate, crystallizes from chloroform/benzene in the orthorhombic space group C2221, with cell parameters a = 14.990 +/- 0.003 A, b = 22.574 +/- 0.004 A, c = 41.112 +/- 0.009 A, V = 13911.7 A3 at 138 K and a calculated density of 1.143 g/cm3 based on C57H89N7O15, 1.5C6H6.H2O and eight formula units per cell. The overall agreement factor R = 0.052 for 7699 reflections, 20 theta max = 150 degrees, Cu K-alpha radiation. The structure determination revealed that didemnin B contains an isostatine residue instead of a statine residue. The conformation of the 23-membered depsipeptide ring is stabilized by one transannular hydrogen bond. The ring does not show the antiparallel beta-pleated-sheet structure but, instead, has a fold in the shape of a bent figure-eight. The linear peptide moiety, containing N-methylleucine and lactylproline, forms a beta (II)-bend and is folded back toward the cyclic backbone, giving the overall molecule a globular character. Comparison with the structure of cyclosporin A shows distinct stereochemical differences between the two molecules. It is suggested that didemnin B and cyclosporin A are unlikely to have a common receptor binding site.
Similar articles
-
Phase II clinical trial of didemnin B in previously treated small cell lung cancer.Invest New Drugs. 1994;12(3):243-9. doi: 10.1007/BF00873966. Invest New Drugs. 1994. PMID: 7896544 Review.
-
Crystal and molecular structure of didemnin A, an antiviral depsipeptide.Int J Pept Protein Res. 1996 Jan-Feb;47(1-2):20-7. doi: 10.1111/j.1399-3011.1996.tb00805.x. Int J Pept Protein Res. 1996. PMID: 8907495
-
Didemnin B. Conformation and dynamics of an antitumour and antiviral depsipeptide studied in solution by 1H and 13C. n.m.r. spectroscopy.Int J Pept Protein Res. 1989 Dec;34(6):445-54. doi: 10.1111/j.1399-3011.1989.tb01393.x. Int J Pept Protein Res. 1989. PMID: 2561421
-
Crystal and molecular structure of Destruxin B.Int J Pept Protein Res. 1988 Feb;31(2):212-9. doi: 10.1111/j.1399-3011.1988.tb00025.x. Int J Pept Protein Res. 1988. PMID: 3366552
-
Natural products as probes of cell biology: 20 years of didemnin research.Med Res Rev. 2002 Mar;22(2):102-45. doi: 10.1002/med.10003. Med Res Rev. 2002. PMID: 11857636 Review.
Cited by
-
Decoding Mammalian Ribosome-mRNA States by Translational GTPase Complexes.Cell. 2016 Nov 17;167(5):1229-1240.e15. doi: 10.1016/j.cell.2016.10.046. Cell. 2016. PMID: 27863242 Free PMC article.
-
Drug development from marine natural products.Nat Rev Drug Discov. 2009 Jan;8(1):69-85. doi: 10.1038/nrd2487. Epub 2008 Dec 19. Nat Rev Drug Discov. 2009. PMID: 19096380 Review.
-
Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B.J Comput Aided Mol Des. 2017 Oct;31(10):915-928. doi: 10.1007/s10822-017-0066-x. Epub 2017 Sep 12. J Comput Aided Mol Des. 2017. PMID: 28900796
-
Diphenic acid as a general conformational lock in the design of bihelical structures.Chemistry. 2007;13(15):4253-63. doi: 10.1002/chem.200601393. Chemistry. 2007. PMID: 17343288 Free PMC article.
-
Phase II clinical trial of didemnin B in previously treated small cell lung cancer.Invest New Drugs. 1994;12(3):243-9. doi: 10.1007/BF00873966. Invest New Drugs. 1994. PMID: 7896544 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
